Pharmaceutical company Elan has said that ‘‘it might make sense’’ to strip off its $1.5 billion development and manufacturing division from its biopharmaceutical business.
The comments follow speculation that the company is preparing to sell off Elan Drug Technology (EDT). Chief financial officer Shane Cooke told analysts that EDT could benefit from being a standalone business.
‘‘If you look at the future potential for both businesses, EDT could benefit from a focus...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team